drugset / Trial / NCT05448599
A Clinical Study of 6MW3211 Monotherapy or Combination Therapy for AML or MDS
NaSingle-groupOpen-labelTreatment
Summary
This study is aimed to evaluate the efficacy, safety, immunogenicity and pharmkinetics, pharmacodynamics of 6MW3211 as monotherapy and in combination with AZA or AZA plus VEN in patients with AML/MDS.
Timeline
- Start
- 2022-07-08
- Primary completion
- 2024-06
- Completion
- 2024-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SAFIMESTOMIG | Monoclonal antibody | 30 mg/kg | Intravenous |
| Subject | SAFIMESTOMIG | Monoclonal antibody | 45 mg/kg | Intravenous |